Partnering

Genocea partners with pharmaceutical and biotechnology companies, universities, government agencies, and foundations in multiple ways including collaborations on Genocea's programs, antigen discovery on new targets, and assisting partners to rapidly build a preclinical vaccine pipeline.

Partners

PATH Foundation and Children's Hospital Boston

In May 2008 Genocea signed a research and collaboration agreement with PATH for the development of a new vaccine to fight Streptococcus pneumonia. PATH, Genocea and Children's Hospital Boston are collaborating on a protein-subunit pneumococcal vaccine for use in the developing world. Genocea will identify pneumococcal antigens recognized by critical immune cells and utilize these proteins for potentially new vaccines against pneumococcus. Learn More

University of Pittsburgh Medical Center's Sexually Transmitted Infections Cooperative Research Center

In December 2009, Genocea was awarded a grant from the University of Pittsburgh Medical Center's (UPMC) Sexually Transmitted Infections (STI) Cooperative Research Center for the development of vaccines for Chlamydia trachomatis. UPMC received a $12.5 million grant from the National Institutes of Health to establish the UPMC STI Cooperative Research Center to advance the understanding of the pathogenesis, diagnosis, prevention, control, and treatment of sexually transmitted infections and associated syndromes. Learn More

Naval Medical Research Center

In April 2010, Genocea entered into a Cooperative Research and Development Agreement (CRADA) with the Naval Medical Research Center (NMRC) for the development of a vaccine against Plasmodium falciparum for the prevention of malaria. Genocea was awarded $2.7 million from the U.S. Army Medical Research and Materiel Command (USAMRMC) to identify T cell antigens using human T-cell screens of a P. falciparum proteomic library. Learn More

Genocea's technology also allows the discovery of antigens that induce T cell responses for treating or preventing other diseases such as cancer, or autoimmune conditions in humans or animals. The technology also has the potential to general diagnostic or prognostic markers for such conditions. These areas represent potential licensing or collaboration opportunities.

Isconova AB, Sweden

In 2009 Genocea entered a research and development collaboration with the Swedish company Isconova AB. Isconova is a biotechnology company specialized in developing and commercializing adjuvants, with a strong patented technology platform. Learn More

For more information, contact [business.development@genocea.com]